| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5694615 | European Urology | 2017 | 9 Pages |
Abstract
Enzalutamide treatment was associated with better health-related quality of life in several domains versus bicalutamide in asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer. This likely relates to previously reported lower rates of symptomatic disease progression.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Axel Heidenreich, Simon Chowdhury, Laurence Klotz, David Robert Siemens, Arnauld Villers, Cristina Ivanescu, Stefan Holmstrom, Benoit Baron, Fong Wang, Ping Lin, Neal D. Shore,